Indacaterol

The First Once-daily Long-acting Beta2 Agonist for COPD

Nonfiction, Health & Well Being, Medical, Specialties, Pulmonary & Thoracic, Medical Science, Pharmacology
Cover of the book Indacaterol by , Springer Basel
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783034807098
Publisher: Springer Basel Publication: November 19, 2013
Imprint: Springer Language: English
Author:
ISBN: 9783034807098
Publisher: Springer Basel
Publication: November 19, 2013
Imprint: Springer
Language: English

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Chronic obstructive pulmonary disease (COPD) is a multi-component condition that results in increasingly limited airflow, usually associated with an abnormal inflammatory response of the lung. It constitutes a major public health burden worldwide, while only very few effective therapies are available.

This book provides a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled β2 agonist for the treatment of COPD. It reviews the current pharmacotherapy for COPD and discusses topics such as the chemical design and the pre-clinical pharmacology of the molecule, the early clinical development, the INHANCE study (which provides a successful example of the use of an adaptive design in the confirmatory setting) and the Phase III clinical efficacy study, as well as the history and performance of the Breezhaler device. Finally, a list of emerging targets is included that could well offer future treatment options for COPD.

More books from Springer Basel

Cover of the book Kripke’s Worlds by
Cover of the book Visual Reasoning with Diagrams by
Cover of the book Matrix Metalloproteinase Inhibitors by
Cover of the book Genomics of Pattern Recognition Receptors by
Cover of the book Ibuprofen: Pharmacology, Therapeutics and Side Effects by
Cover of the book Fractal Symmetry of Protein Interior by
Cover of the book Around and Beyond the Square of Opposition by
Cover of the book Lentiviral Vectors and Gene Therapy by
Cover of the book And Yet It Is Heard by
Cover of the book Immunosenescence by
Cover of the book Berichte zur Resistenzmonitoringstudie 2009 by
Cover of the book Viral Infections of the Human Nervous System by
Cover of the book Infection, Immune Homeostasis and Immune Privilege by
Cover of the book Fluorescent Methods for Molecular Motors by
Cover of the book A Comprehensive Treatment of q-Calculus by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy